A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

开始日期2022-12-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171075

/ Recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

开始日期2022-09-27

申办/合作机构

Anthos Therapeutics, Inc.

NCT05171049

/ Active, not recruiting临床3期

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

开始日期2022-05-05

申办/合作机构

Anthos Therapeutics, Inc.

100 项与 Abelacimab 相关的临床结果

登录后查看更多信息

100 项与 Abelacimab 相关的转化医学

登录后查看更多信息

100 项与 Abelacimab 相关的专利（医药）

登录后查看更多信息

项与 Abelacimab 相关的文献（医药）

2025-09-01·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

DOAC–Stop reverses the anticoagulant effect of asundexian and milvexian

Article

作者: Fitzpatrick, Ella K ; Weitz, Jeffrey I ; Fredenburgh, James C

BACKGROUND:

Asundexian and milvexian are small-molecule factor (F)XIa inhibitors, whereas abelacimab is an antibody that binds FXI and blocks its activation and activity. All 3 FXI inhibitors are currently undergoing phase 3 evaluation. Similar to heparin and dabigatran, asundexian, milvexian, and abelacimab prolong the activated partial thromboplastin time (APTT) in a concentration-dependent manner. DOAC-Stop (DS) is an activated charcoal-based compound that adsorbs direct oral anticoagulants such as dabigatran, but not heparin, from plasma. It is unknown whether DS also neutralizes asundexian and milvexian.

OBJECTIVE:

This study aimed to determine whether DS reverses the prolongation of the APTT caused by asundexian or milvexian. Dabigatran was used as a positive control, while abelacimab and heparin served as negative controls.

METHODS:

The APTT in human plasma, with or without asundexian, milvexian, abelacimab, dabigatran, or heparin, was determined before and after DS treatment.

RESULTS:

As expected, all drugs produced concentration-dependent prolongation of the APTT. DS returned the APTT to baseline values with asundexian, milvexian, and dabigatran, but not with abelacimab or heparin. The APTT was prolonged in a more than additive manner with the combination of 2.5 μM milvexian and 0.125 U/mL heparin. However, DS reversed only the APTT prolongation induced by milvexian, but not that by heparin.

CONCLUSION:

DS reverses the effect of asundexian and milvexian on the APTT and distinguishes between the APTT effects of milvexian and heparin.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

Article

作者: Goodrich, Erica L. ; Bloomfield, Dan ; Wojakowski, Wojciech ; Murphy, Sabina A. ; Morrow, David A. ; Weitz, Jeffrey I. ; Patel, Siddharth M. ; Parkar, Sanobar ; Giugliano, Robert P. ; Goodman, Shaun G. ; Sabatine, Marc S. ; Kiss, Robert G. ; Ruff, Christian T. ; Joung, Boyoung ; Chen, Shih-Ann ; Hug, Bruce ; Al Said, Samer

BACKGROUND::

Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.

METHODS::

This prespecified analysis of AZALEA-TIMI 71, which randomized patients between March and December of 2021 to 1 of 2 subcutaneous monthly abelacimab doses (90 or 150 mg) or oral rivaroxaban (20 mg daily, dose reduced to 15 mg in patients with creatinine clearance ≤50 mL/min), stratified patients by planned use of concomitant APT. The primary composite end point of major or clinically relevant nonmajor bleeding and other safety and efficacy outcomes were examined by concomitant APT and randomized treatment.

RESULTS::

Of 1287 patients (44% female; median age 74 years [interquartile range, 69–78]), 318 (24.7%) were on APT at baseline with planned continuation (15.5% aspirin only, 7.5% P2Y 12 inhibitor only, and 1.6% dual APT). In the rivaroxaban arm, the rate of major or clinically relevant nonmajor bleeding was 10.6 per 100 patient-years with concomitant APT versus 7.7 per 100 patient-years without. In the abelacimab arms, the rates were 2.5 and 3.5 per 100 patient-years for the 90-mg and 150-mg doses, respectively, with concomitant APT and 2.7 and 3.1 per 100 patient-years without. Each abelacimab dose significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban, both in those with concomitant APT (adjusted hazard ratio, 0.26 [95% CI, 0.10–0.70] and 0.30 [95% CI, 0.12–0.74] for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) and in those without concomitant APT (adjusted hazard ratio, 0.34 [95% CI, 0.19–0.60] and 0.40 [95% CI, 0.23–0.68] for 90 mg and 150 mg of abelacimab, respectively; Pinteractions =0.56 and 0.60, respectively). Patients with concomitant APT tended to derive greater absolute risk reductions with abelacimab (8.1 and 7.1 for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) than those without concomitant APT (5.0 and 4.6, respectively).

CONCLUSIONS::

Inhibition of factor XI with abelacimab consistently reduced bleeding compared with rivaroxaban regardless of concomitant APT use, with greater absolute reductions in bleeding in those requiring concomitant APT. These data suggest that factor XI inhibition may be a safe anticoagulant option in patients with atrial fibrillation requiring concomitant APT.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04755283.

2025-08-05·CIRCULATION

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?

Communications

作者: Steg, Philippe Gabriel ; Mesnier, Jules

126

项与 Abelacimab 相关的新闻（医药）

2025-09-09

·BioSpace

Novartis Deals in Cardio Again, Dropping $1.4B to Acquire Tourmaline

iStock, TBE Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others. For the fourth time this year, Novartis is using its wallet to beef up its heart disease pipeline, acquiring New York-based Tourmaline Bio. Under the terms of the deal, announced early on Tuesday , Novartis, through an “indirect, wholly owned” but undisclosed subsidiary, will purchase all of Tourmaline’s outstanding shares for $48 apiece—an offer that, according to analysts at Truist Securities, represents a roughly 60% premium on the biotech’s closing trade price on Monday. All told, the acquisition agreement values Tourmaline at around $1.4 billion on a fully diluted basis. Truist, in a Tuesday morning note, called the transaction “a good deal” given the pharma’s “strong footprint” in the cardiovascular space. The companies expect to complete the buyout in the fourth quarter, pending customary conditions. The respective boards of directors of both companies have already unanimously signed off on the arrangement. Shares of Tourmaline were up 13% at close Monday and are up 58% in pre-market trading Tuesday. The centerpiece of the acquisition is pacibekitug, an investigational monoclonal antibody that works by targeting the IL-6 protein and is being trialed for atherosclerotic cardiovascular disease (ASCVD). In May, Tourmaline presented topline data from the Phase II TRANQUILITY study, touting a “ rapid, deep, and durable ” reduction in levels of high-sensitivity C-reactive protein, a key marker of inflammation linked to elevated cardiovascular disease. At the time, Tourmaline positioned findings from TRANQUILITY as the “starting point” of the clinical development program of pacibekitug in ASCVD and other cardiovascular conditions. Pacibekitug “represents a potential breakthrough” in lowering residual inflammation in ASCVD patients, Novartis Chief Medical Officer Shreeram Aradhye said in a statement on Tuesday. Novartis has yet to provide details regarding its plans for pacibekitug moving forward. Tuesday’s acquisition of Tourmaline comes shortly after Novartis expanded its partnership with China’s Argo Biopharmaceutical. The pharma last week paid $160 million upfront and pledged up to $5.2 billion in milestone payments to collaborate on “multiple” RNAi assets for cardiovascular disease, as well as leveraging the biotech’s siRNA drug development platform. Argo and Novartis first partnered in January 2024 . Novartis in February also put $3.1 billion on the line to acquire private biotech Anthos Therapeutics and regain the rights to its anticoagulant antibody abelacimab. Then, in June, the pharma entered into a multi-target arrangement with Flagship Pioneering’s ProFound Therapeutics to develop novel protein therapies for cardiovascular conditions. This agreement involved a $25 million upfront payment and up to $750 million in milestones per target.

并购临床2期临床结果

2025-09-03

·BioSpace

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment

iStock, Tamer Soliman Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases. Novartis and Shanghai-based Argo Biopharmaceutical are deepening their relationship with a new multibillion-dollar agreement that will see the partners work on multiple siRNA assets for cardiovascular targets. Under the terms of the deal, announced Wednesday, Novartis will front Argo $160 million and commit up to $5.2 billion in milestone and option payments. Argo, meanwhile, will additionally be entitled to tiered royalties. Novartis and Argo first linked up in January 2024 with two license and collaboration agreements for investigational cardiovascular RNAi therapies. Those initial deals totaled $185 million upfront plus up to $4.165 billion in milestones. Wednesday’s new agreement covers “multiple” cardiovascular candidates from Argo’s pipeline, though the companies did not specify how many assets they will work on together. Argo brings to the table its siRNA drug discovery engine, which aims to produce more stable, long-acting siRNA molecules, according to its website . These long-acting siRNA therapies “represent an important paradigm shift in prevention and treatment of cardiovascular diseases,” Shaun Coughlin, global head of Cardiovascular and Metabolism at Novartis Biomedical Research, said in the companies’ announcement. The Argo agreements, he added, strengthen “our efforts to advance potential new therapies that address unmet medical needs.” Novartis’ $5.2 billion-plus bet with Argo is the third—and heftiest—deal the pharma has signed in just over a week. On Aug. 26, Novartis put $772 million on the line in a collaboration with BioArctic, gaining access to its BrainTransporter platform to advance therapies for neurodegenerative diseases that can cross the blood-brain barrier. Then, on Tuesday, the pharma joined up with Arrowhead Pharmaceuticals to develop an RNAi therapy for Parkinson’s disease, paying $200 million upfront and pledging up to $2 billion in milestones. Novartis has been busy in dealmaking this year. In June, for instance, the company signed a $750-million-per-target agreement with Flagship Pioneering’s ProFound Therapeutics for protein therapies for cardiovascular diseases. And in April, the company paid $800 million upfront and bet up to $1.7 billion to acquire Regulus Therapeutics , gaining ownership of the oligonucleotide farabursen, being developed for autosomal dominant polycystic kidney disease. A few months earlier, in February, Novartis dropped $3.1 billion to buy the privately held Anthos Therapeutics, gaining ownership of the anticoagulant antibody abelacimab.

并购引进/卖出寡核苷酸

2025-08-18

·GlobeNewswire-Health Care

New Novartis ESC data highlights strength of cardiovascular portfolio

PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein apheresis – a cholesterol removal procedure similar to dialysisPARACHUTE-HF study will highlight the efficacy and safety of Entresto to treat heart failure with reduced ejection fraction due to chronic Chagas diseaseAdditional presentations will assess the safety of new pipeline asset abelacimab in atrial fibrillation Basel, August 18, 2025 – Novartis will present data from 19 abstracts across its cardiovascular portfolio at the 2025 European Society of Cardiology (ESC) Congress in Madrid from August 29 to September 1, 2025. “The latest data we are presenting at ESC will showcase how Novartis is pioneering groundbreaking treatments that can transform cardiovascular outcomes,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. “With established treatments Entresto and Leqvio, we continue to explore new ways to improve patient care whilst also investigating broader populations who may benefit. With promising pipeline assets, pelacarsen and abelacimab, we are tackling areas of significant unmet need to address the myriad of factors that cause or worsen heart disease.” Key highlights of data accepted by ESC include: Medicine Presentation Title Presentation Details Pelacarsen Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial Station 12 (Research Gateway) Moderated ePoster August 29, 09:15-10:00 CEST Pelacarsen Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database Station 2 (Research Gateway) Moderated ePoster August 30, 17:15 – 18:00 CEST Pelacarsen Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England Discovery Pole (North Convention Centre) Poster August 29, 15:15 CEST Leqvio VICTORION-Difference study: Inclisiran-based strategy vs standard of care Madrid (Main Auditorium) Hot Line August 30, 17:00 CEST Leqvio VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C Discovery Pole (North Convention Centre) Poster August 29, 10:00 CEST Abelacimab Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 14:30 CEST Abelacimab Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 15:00 CEST Entresto PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy Madrid (Main Auditorium) Hot Line September 1, 8:15 CEST About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud of the positive impact we’ve made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: media.relations@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

临床3期AHA会议

100 项与 Abelacimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性栓塞	临床3期	美国	Lonza AG	2022-12-27
全身性栓塞	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	日本	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	日本	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Lonza AG	2022-12-27
全身性栓塞	临床3期	加拿大	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Anthos Therapeutics, Inc.	2022-12-27
全身性栓塞	临床3期	以色列	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Lonza AG	2022-12-27
心房颤动	临床3期	美国	Anthos Therapeutics, Inc.	2022-12-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	临床2期	脑卒中 \| 心房颤动	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	窪廠壓艱鏇鹽遞獵遞製 = 齋遞簾憲築積鹹遞餘齋簾繭襯淵繭夢鑰積獵夢 (憲觸鏇壓選鏇繭壓遞構, 壓鏇遞範壓鑰鑰觸窪願 ~ 範鬱窪繭繭遞齋觸獵糧) 更多	-	2025-07-30
				Abelacimab (Abelacimab 150 mg (MAA868))	窪廠壓艱鏇鹽遞獵遞製 = 願鏇築齋膚願網壓壓蓋簾繭襯淵繭夢鑰積獵夢 (憲觸鏇壓選鏇繭壓遞構, 夢鏇鏇衊夢構糧構窪憲 ~ 壓廠艱製衊獵製餘齋築) 更多
NCT04755283 (AZALEA-TIMI 71, Company_Website) 人工标引	临床2期	出血 \| 心房颤动	-	abelacimab (≥75 years)	蓋糧鹹鏇壓遞顧醖壓廠(鹽鹽鬱遞願壓壓憲鹹網) = 繭餘衊餘網膚鬱網鹹顧顧簾構觸憲鹹鬱壓鏇夢 (網願壓醖鏇窪網夢衊艱 )	积极	2025-04-08
				abelacimab (＜75 years)	蓋糧鹹鏇壓遞顧醖壓廠(鹽鹽鬱遞願壓壓憲鹹網) = 積衊願鏇衊齋醖夢鬱糧顧簾構觸憲鹹鬱壓鏇夢 (網願壓醖鏇窪網夢衊艱 )
NCT04755283 (AZALEA-TIMI 71, Pubmed) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mgAbelacimab 150 mg	範艱衊鏇簾衊醖製糧願(襯鬱網鹹製窪簾網窪選) = 築廠鏇齋築廠遞衊獵製願憲築觸選顧淵糧製餘 (襯鑰獵願醖襯積築醖願 )	积极	2025-01-23
				AbelacimabAbelacimab 90 mg	範艱衊鏇簾衊醖製糧願(襯鬱網鹹製窪簾網窪選) = 網憲鹽鹽顧鑰製廠鏇襯願憲築觸選顧淵糧製餘 (襯鑰獵願醖襯積築醖願 )
NCT04755283 (AZALEA-TIMI 71, GlobeNewswire) 人工标引	临床2期	血栓形成	-	Abelacimab 150 mg	糧範築餘膚觸壓鹹鬱蓋(選蓋糧獵製衊廠觸構餘) = 壓蓋襯襯憲艱繭觸餘窪鬱鑰膚衊餘衊淵醖鬱築 (蓋鏇網憲壓遞蓋膚憲鏇 )	积极	2024-11-16
				Rivaroxaban	糧範築餘膚觸壓鹹鬱蓋(選蓋糧獵製衊廠觸構餘) = 廠築憲齋繭淵鏇淵夢願鬱鑰膚衊餘衊淵醖鬱築 (蓋鏇網憲壓遞蓋膚憲鏇 )
NCT04755283 (AZALEA-TIMI 71, PipelineReview) 人工标引	N/A	心房颤动	1,287	abelacimab 150 mg	夢顧淵蓋遞鬱壓遞網願(鏇築簾築艱簾壓膚網鏇) = 艱鏇鏇製廠遞衊範糧獵膚醖衊鏇獵蓋構願淵淵 (窪築遞獵廠餘獵衊鬱鬱 ) 更多	积极	2023-11-13
				rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71 , Corporate Publications) 人工标引	临床2期	心房颤动	1,287	Abelacimab 150 mg	顧衊構繭願壓淵窪醖製(齋餘築製繭艱蓋獵鹽醖) = 鑰製艱顧膚築鹹齋繭網齋構淵廠範鹹蓋廠餘鏇 (淵願遞鹹製糧鹽願遞膚 ) 更多	优效	2023-11-12
				Rivaroxaban 20 mg	-
NCT04755283 (AZALEA-TIMI 71, Biospace) 人工标引	临床2期	心房颤动	1,287	Abelacimab	築顧願鬱鏇夢糧醖觸鬱(獵衊餘鹹蓋願憲願積簾) = met 壓鑰築艱襯願蓋繭顧獵 (願淵遞窪選製蓋製鏇窪 ) 达到	积极	2023-09-18
				Rivaroxaban
NCT04213807 (CTgov)	临床2期	心房颤动	28	Placebo	廠廠鏇襯齋窪壓襯遞蓋 = 鹽窪繭醖獵遞艱鑰夢觸鹹鬱顧壓獵構製築糧網 (衊齋壓鹽選淵淵淵製齋, 膚衊齋選淵構夢艱餘繭 ~ 壓鏇範蓋醖鏇鑰築襯積) 更多	-	2021-12-07
EUCTR2019-003756-37-BG (ANT-005 TKA, ISTH2021 \| Company_Website) 人工标引	临床2期	静脉血栓栓塞	412	30mg abelacimab	艱顧蓋衊顧選築憲願壓(遞廠膚鹹願製壓積鬱壓) = 繭築窪鬱鹽襯構範繭醖繭蓋構繭廠蓋餘顧觸觸 (鏇觸獵艱鹹鹽糧製廠蓋 ) 更多	积极	2021-07-17
				75mg abelacimab	艱顧蓋衊顧選築憲願壓(遞廠膚鹹願製壓積鬱壓) = 獵獵網壓製齋獵顧齋淵繭蓋構繭廠蓋餘顧觸觸 (鏇觸獵艱鹹鹽糧製廠蓋 ) 更多